TWI838114B - 黑皮質素-4受體激動劑在預防或治療罕見遺傳性肥胖中的用途 - Google Patents
黑皮質素-4受體激動劑在預防或治療罕見遺傳性肥胖中的用途 Download PDFInfo
- Publication number
- TWI838114B TWI838114B TW112104117A TW112104117A TWI838114B TW I838114 B TWI838114 B TW I838114B TW 112104117 A TW112104117 A TW 112104117A TW 112104117 A TW112104117 A TW 112104117A TW I838114 B TWI838114 B TW I838114B
- Authority
- TW
- Taiwan
- Prior art keywords
- acid
- compound
- pyrrolidine
- pomc
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20220016377 | 2022-02-08 | ||
| KR10-2022-0016377 | 2022-02-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202339761A TW202339761A (zh) | 2023-10-16 |
| TWI838114B true TWI838114B (zh) | 2024-04-01 |
Family
ID=87564659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112104117A TWI838114B (zh) | 2022-02-08 | 2023-02-06 | 黑皮質素-4受體激動劑在預防或治療罕見遺傳性肥胖中的用途 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250134898A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4461297A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025505229A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230120106A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119300835A (cg-RX-API-DMAC7.html) |
| AR (1) | AR128463A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023218785A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3248118A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024002389A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2024011882A2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024009854A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI838114B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023153762A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3202315A1 (en) * | 2020-12-22 | 2022-06-30 | Hee Dong Park | Use as selective agonist of malanocortin-4 receptor |
| KR20250046623A (ko) * | 2023-09-27 | 2025-04-03 | 주식회사 엘지화학 | 멜라노코르틴-4 수용체 효능제의 pcsk1 결핍 적응증과 연관된 희귀성 유전적 비만질환의 예방 또는 치료 용도 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200813032A (en) * | 2006-07-14 | 2008-03-16 | Lg Life Sciences Ltd | Melanocortin receptor agonists |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12516047B2 (en) * | 2019-11-07 | 2026-01-06 | Lg Chem, Ltd. | Melanocortin-4 receptor agonists |
| CN116507615A (zh) * | 2020-10-29 | 2023-07-28 | 株式会社Lg化学 | 黑皮质素受体激动剂化合物的晶型i及其制备方法 |
| TWI804170B (zh) * | 2021-01-21 | 2023-06-01 | 南韓商Lg化學股份有限公司 | 黑皮質素-4受體促效劑的用途 |
| TWI826938B (zh) * | 2021-02-26 | 2023-12-21 | 南韓商Lg化學股份有限公司 | 黑皮質素-4受體促效劑 |
| TWI861780B (zh) * | 2022-03-28 | 2024-11-11 | 南韓商Lg化學股份有限公司 | 預防或治療肥胖的聯合療法 |
-
2023
- 2023-02-06 TW TW112104117A patent/TWI838114B/zh active
- 2023-02-07 US US18/837,125 patent/US20250134898A1/en active Pending
- 2023-02-07 EP EP23753110.8A patent/EP4461297A4/en active Pending
- 2023-02-07 CN CN202380032193.6A patent/CN119300835A/zh active Pending
- 2023-02-07 CA CA3248118A patent/CA3248118A1/en active Pending
- 2023-02-07 JP JP2024547302A patent/JP2025505229A/ja active Pending
- 2023-02-07 KR KR1020230016160A patent/KR20230120106A/ko not_active Ceased
- 2023-02-07 AR ARP230100283A patent/AR128463A1/es unknown
- 2023-02-07 AU AU2023218785A patent/AU2023218785A1/en active Pending
- 2023-02-07 WO PCT/KR2023/001712 patent/WO2023153762A1/ko not_active Ceased
-
2024
- 2024-08-08 CL CL2024002389A patent/CL2024002389A1/es unknown
- 2024-08-12 MX MX2024009854A patent/MX2024009854A/es unknown
- 2024-08-30 CO CONC2024/0011882A patent/CO2024011882A2/es unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200813032A (en) * | 2006-07-14 | 2008-03-16 | Lg Life Sciences Ltd | Melanocortin receptor agonists |
Non-Patent Citations (2)
| Title |
|---|
| 期刊 Peter Kühnen, M.D., et al., Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist, N Engl J Med, 375:240-246, 2016/07/21 * |
| 期刊 Peter Kühnen, M.D., et al., Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist, N Engl J Med, 375:240-246, 2016/07/21。 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025505229A (ja) | 2025-02-21 |
| AU2023218785A1 (en) | 2024-08-22 |
| CA3248118A1 (en) | 2025-01-24 |
| WO2023153762A1 (ko) | 2023-08-17 |
| EP4461297A4 (en) | 2025-04-09 |
| CL2024002389A1 (es) | 2025-01-31 |
| TW202339761A (zh) | 2023-10-16 |
| CN119300835A (zh) | 2025-01-10 |
| AR128463A1 (es) | 2024-05-08 |
| CO2024011882A2 (es) | 2025-01-23 |
| EP4461297A1 (en) | 2024-11-13 |
| US20250134898A1 (en) | 2025-05-01 |
| KR20230120106A (ko) | 2023-08-16 |
| MX2024009854A (es) | 2024-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI861780B (zh) | 預防或治療肥胖的聯合療法 | |
| TWI804170B (zh) | 黑皮質素-4受體促效劑的用途 | |
| EP4461297A1 (en) | Use of melanocortin-4 receptor agonist in preventing or treating rare genetic obesity disease | |
| EP4299572A1 (en) | Melanocortin-4 receptor agonist | |
| EP4265255A1 (en) | Use as selective agonist of malanocortin-4 receptor | |
| CN117242064A (zh) | 黑皮质素受体激动剂化合物的晶型v及其制备方法 | |
| RU2850792C1 (ru) | Применение агониста рецептора меланокортина-4 | |
| HK40119184A (en) | Use of melanocortin-4 receptor agonist in preventing or treating rare genetic obesity disease | |
| KR20250108398A (ko) | Lepr 이형접합 결핍 희귀성 유전적 비만 질환의 예방, 개선 또는 치료에서의 멜라노코르틴-4 수용체 효능제의 용도 | |
| KR20250100260A (ko) | Sh2b1 결핍 희귀성 유전적 비만 질환의 예방, 개선 또는 치료에서의 멜라노코르틴-4 수용체 효능제의 용도 | |
| AU2024351762A1 (en) | Use of melanocortin-4 receptor agonists for the treatment of pcsk1 deficiency indications | |
| WO2025144899A1 (en) | Use of melanocortin-4 receptor agonists for the treatment of a lepr and/or sh2b1 deficiency |